Trypanosoma cruzi adjuvants potentiate T cell-mediated immunity induced by a NY-ESO-1 based antitumor vaccine.
Immunological adjuvants that induce T cell-mediate immunity (TCMI) with the least side effects are needed for the development of human vaccines. Glycoinositolphospholipids (GIPL) and CpGs oligodeoxynucleotides (CpG ODNs) derived from the protozoa parasite Trypanosoma cruzi induce potent pro-inflamma...
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3342165?pdf=render |
id |
doaj-c0a544502a4b4f519e0166b7715ce83b |
---|---|
record_format |
Article |
spelling |
doaj-c0a544502a4b4f519e0166b7715ce83b2020-11-25T01:00:09ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-0175e3624510.1371/journal.pone.0036245Trypanosoma cruzi adjuvants potentiate T cell-mediated immunity induced by a NY-ESO-1 based antitumor vaccine.Caroline JunqueiraAna Tereza GuerreroBruno Galvão-FilhoWarrison A AndradeAna Paula C SalgadoThiago M CunhaCatherine RopertMarco Antônio CamposMarcus L O PenidoLúcia Mendonça-PreviatoJosé Oswaldo PreviatoGerd RitterFernando Q CunhaRicardo T GazzinelliImmunological adjuvants that induce T cell-mediate immunity (TCMI) with the least side effects are needed for the development of human vaccines. Glycoinositolphospholipids (GIPL) and CpGs oligodeoxynucleotides (CpG ODNs) derived from the protozoa parasite Trypanosoma cruzi induce potent pro-inflammatory reaction through activation of Toll-Like Receptor (TLR)4 and TLR9, respectively. Here, using mouse models, we tested the T. cruzi derived TLR agonists as immunological adjuvants in an antitumor vaccine. For comparison, we used well-established TLR agonists, such as the bacterial derived monophosphoryl lipid A (MPL), lipopeptide (Pam3Cys), and CpG ODN. All tested TLR agonists were comparable to induce antibody responses, whereas significant differences were noticed in their ability to elicit CD4(+) T and CD8(+) T cell responses. In particular, both GIPLs (GTH, and GY) and CpG ODNs (B344, B297 and B128) derived from T. cruzi elicited interferon-gamma (IFN-γ) production by CD4(+) T cells. On the other hand, the parasite derived CpG ODNs, but not GIPLs, elicited a potent IFN-γ response by CD8(+) T lymphocytes. The side effects were also evaluated by local pain (hypernociception). The intensity of hypernociception induced by vaccination was alleviated by administration of an analgesic drug without affecting protective immunity. Finally, the level of protective immunity against the NY-ESO-1 expressing melanoma was associated with the magnitude of both CD4(+) T and CD8(+) T cell responses elicited by a specific immunological adjuvant.http://europepmc.org/articles/PMC3342165?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Caroline Junqueira Ana Tereza Guerrero Bruno Galvão-Filho Warrison A Andrade Ana Paula C Salgado Thiago M Cunha Catherine Ropert Marco Antônio Campos Marcus L O Penido Lúcia Mendonça-Previato José Oswaldo Previato Gerd Ritter Fernando Q Cunha Ricardo T Gazzinelli |
spellingShingle |
Caroline Junqueira Ana Tereza Guerrero Bruno Galvão-Filho Warrison A Andrade Ana Paula C Salgado Thiago M Cunha Catherine Ropert Marco Antônio Campos Marcus L O Penido Lúcia Mendonça-Previato José Oswaldo Previato Gerd Ritter Fernando Q Cunha Ricardo T Gazzinelli Trypanosoma cruzi adjuvants potentiate T cell-mediated immunity induced by a NY-ESO-1 based antitumor vaccine. PLoS ONE |
author_facet |
Caroline Junqueira Ana Tereza Guerrero Bruno Galvão-Filho Warrison A Andrade Ana Paula C Salgado Thiago M Cunha Catherine Ropert Marco Antônio Campos Marcus L O Penido Lúcia Mendonça-Previato José Oswaldo Previato Gerd Ritter Fernando Q Cunha Ricardo T Gazzinelli |
author_sort |
Caroline Junqueira |
title |
Trypanosoma cruzi adjuvants potentiate T cell-mediated immunity induced by a NY-ESO-1 based antitumor vaccine. |
title_short |
Trypanosoma cruzi adjuvants potentiate T cell-mediated immunity induced by a NY-ESO-1 based antitumor vaccine. |
title_full |
Trypanosoma cruzi adjuvants potentiate T cell-mediated immunity induced by a NY-ESO-1 based antitumor vaccine. |
title_fullStr |
Trypanosoma cruzi adjuvants potentiate T cell-mediated immunity induced by a NY-ESO-1 based antitumor vaccine. |
title_full_unstemmed |
Trypanosoma cruzi adjuvants potentiate T cell-mediated immunity induced by a NY-ESO-1 based antitumor vaccine. |
title_sort |
trypanosoma cruzi adjuvants potentiate t cell-mediated immunity induced by a ny-eso-1 based antitumor vaccine. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2012-01-01 |
description |
Immunological adjuvants that induce T cell-mediate immunity (TCMI) with the least side effects are needed for the development of human vaccines. Glycoinositolphospholipids (GIPL) and CpGs oligodeoxynucleotides (CpG ODNs) derived from the protozoa parasite Trypanosoma cruzi induce potent pro-inflammatory reaction through activation of Toll-Like Receptor (TLR)4 and TLR9, respectively. Here, using mouse models, we tested the T. cruzi derived TLR agonists as immunological adjuvants in an antitumor vaccine. For comparison, we used well-established TLR agonists, such as the bacterial derived monophosphoryl lipid A (MPL), lipopeptide (Pam3Cys), and CpG ODN. All tested TLR agonists were comparable to induce antibody responses, whereas significant differences were noticed in their ability to elicit CD4(+) T and CD8(+) T cell responses. In particular, both GIPLs (GTH, and GY) and CpG ODNs (B344, B297 and B128) derived from T. cruzi elicited interferon-gamma (IFN-γ) production by CD4(+) T cells. On the other hand, the parasite derived CpG ODNs, but not GIPLs, elicited a potent IFN-γ response by CD8(+) T lymphocytes. The side effects were also evaluated by local pain (hypernociception). The intensity of hypernociception induced by vaccination was alleviated by administration of an analgesic drug without affecting protective immunity. Finally, the level of protective immunity against the NY-ESO-1 expressing melanoma was associated with the magnitude of both CD4(+) T and CD8(+) T cell responses elicited by a specific immunological adjuvant. |
url |
http://europepmc.org/articles/PMC3342165?pdf=render |
work_keys_str_mv |
AT carolinejunqueira trypanosomacruziadjuvantspotentiatetcellmediatedimmunityinducedbyanyeso1basedantitumorvaccine AT anaterezaguerrero trypanosomacruziadjuvantspotentiatetcellmediatedimmunityinducedbyanyeso1basedantitumorvaccine AT brunogalvaofilho trypanosomacruziadjuvantspotentiatetcellmediatedimmunityinducedbyanyeso1basedantitumorvaccine AT warrisonaandrade trypanosomacruziadjuvantspotentiatetcellmediatedimmunityinducedbyanyeso1basedantitumorvaccine AT anapaulacsalgado trypanosomacruziadjuvantspotentiatetcellmediatedimmunityinducedbyanyeso1basedantitumorvaccine AT thiagomcunha trypanosomacruziadjuvantspotentiatetcellmediatedimmunityinducedbyanyeso1basedantitumorvaccine AT catherineropert trypanosomacruziadjuvantspotentiatetcellmediatedimmunityinducedbyanyeso1basedantitumorvaccine AT marcoantoniocampos trypanosomacruziadjuvantspotentiatetcellmediatedimmunityinducedbyanyeso1basedantitumorvaccine AT marcuslopenido trypanosomacruziadjuvantspotentiatetcellmediatedimmunityinducedbyanyeso1basedantitumorvaccine AT luciamendoncapreviato trypanosomacruziadjuvantspotentiatetcellmediatedimmunityinducedbyanyeso1basedantitumorvaccine AT joseoswaldopreviato trypanosomacruziadjuvantspotentiatetcellmediatedimmunityinducedbyanyeso1basedantitumorvaccine AT gerdritter trypanosomacruziadjuvantspotentiatetcellmediatedimmunityinducedbyanyeso1basedantitumorvaccine AT fernandoqcunha trypanosomacruziadjuvantspotentiatetcellmediatedimmunityinducedbyanyeso1basedantitumorvaccine AT ricardotgazzinelli trypanosomacruziadjuvantspotentiatetcellmediatedimmunityinducedbyanyeso1basedantitumorvaccine |
_version_ |
1725214871390257152 |